Bring state and pharma together to solve Greek access woes, says trade group

The Hellenic Association of Pharmaceutical Companies (SFEE)—Greek pharma’s trade association—has presented results from studies concerning patients’ access to new, innovative treatments, the availability of innovative medicines and public funding for medicine.

According to the Patients W.A.I.T. Indicator 2023 from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and IQVIA, less pharma innovation is now reaching Greek patients, with 79 out of 167 new drugs coming to Greece between 2019 and 2022, compared to 90 out of 168 in 2018 to 2021.

For these medicines, it takes an average of 587 days from their European approval until they are reimbursed in Greece. This is almost two months below the European average, but has improved by 74 days compared to the previous period.